Table 5. Correlation between common oncogene mutations or rearrangement and PD-L1 over-expression.
| Gene | Mutation | Wild-type | PD-L1 TPS ≥50% in mutation | PD-L1 TPS ≥50% in wild-type | P |
|---|---|---|---|---|---|
| EGFR | 68 | 55 | 10.3% (7/68) | 29.1% (16/55) | 0.007 |
| ALK | 11 | 112 | 18.2% (2/11) | 18.8% (21/112) | 0.72 |
| KRAS | 16 | 107 | 25.0% (4/16) | 17.8% (19/107) | 0.73 |
| TP53 | 63 | 60 | 20.6% (13/63) | 16.7% (10/60) | 0.57 |
| KRAS/TP53 | 7 | 116 | 28.6% (2/7) | 18.1% (21/116) | 0.49 |
| RET | 3 | 120 | 33.3% (1/3) | 18.3% (22/120) | 0.93 |
| BRAF | 9 | 114 | 44.4% (4/9) | 16.7% (19/114) | 0.11 |
| ERBB2 | 7 | 116 | 0.0% (0/7) | 19.8% (23/116) | 0.42 |
| PIK3CA | 9 | 114 | 0.0% (0/9) | 20.2% (23/114) | 0.29 |
| STK11 | 6 | 117 | 16.7% (1/6) | 18.8% (22/117) | 0.68 |
PD-L1, programmed death ligand 1; TPS, tumor proportion score.